Skip to main content
SpringerLink
Log in

Pharmacological Treatments

  • Chapter
Cocaine

Part of the book series: Drugs of Abuse ((DOAC,volume 3))

  • 127 Accesses

Abstract

At this time, the pharmacological treatments for cocaine addiction are adjunctive and are not intended as exclusive stand-alone treatments. Rather, their primary utility stems from helping patients to remain abstinent and involved in other therapies while coping with the craving and withdrawal associated with cocaine. Pharmacological treatments may be used for any bona fide preexisting or concurrent psychiatric conditions. As a result, these pharmacological treatments can be valuable tools in helping a patient to benefit from the behavioral, rehabilitative, psychotherapeutic, family, and group therapy (including self-help) treatment regimen used to promote a successful recovery. Nevertheless, our increasing knowledge of the physiological effects of cocaine has led to numerous attempts to improve and widen the scope of the pharmacotherapy. Table 7.1 lists the most common pharmacological treatments for cocaine dependence.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Weiss RD, Mirin SM. Psychological and pharmacological treatment strategies in cocaine dependence. Ann Clin Psychiatry. 1990;2:239–243.

    Article  Google Scholar 

  2. Vaughan RA, Simantov R, Lew R, Kuhar MJ. A rapid binding assay for solubilized dopamine transporters using [3H]WIN 35,428. J Neurosci Methods. 1991;40:9–16.

    Article  PubMed  CAS  Google Scholar 

  3. Goldfrank LR, Hoffman RS. American Association of Poison Control Centers National Data Collection System. Ann Emerg Med. 1991;20:165–170.

    Article  PubMed  CAS  Google Scholar 

  4. Post RM, Weiss SRB, Aigner TC. Carbamazepine in the treatment of cocaine abuse. Paper presented at the Conference on the Biological Basis of Addiction; Santa Monica, Calif; January 11, 1991.

    Google Scholar 

  5. Golwyn DH. Cocaine abuse treated with phenelzine. Int J Addict. 1988;23:897–905.

    PubMed  CAS  Google Scholar 

  6. Gawin FH, Kleber HD, Byck R, et al. Desipramine facilitation of initial cocaine abstinence. Arch Gen Psychiatry. 1989;46:117–121.

    Article  PubMed  CAS  Google Scholar 

  7. Weiss RD, Pope HG Jr, Mirin SM. Treatment of chronic abuse and attention deficit disorder, residual type, with magnesium pemoline. Drug Alcohol Depend. 1985;15:69–72.

    Article  PubMed  CAS  Google Scholar 

  8. Khantzian EJ. An extreme case of cocaine dependence and marked improvement with methylphenidate treatment. Am J Psychiatry. 1983;140:784–785.

    PubMed  CAS  Google Scholar 

  9. Wise RA. The neurobiology of craving: implications for the understanding and treatment of addiction. J Abnormal Psychol 1988;97(2)118–132.

    Article  CAS  Google Scholar 

  10. Gold MS, Pottash ALC, Extein I, et al. Clonidine in acute opiate withdrawal. N Eng J Med. 1980;302:1421.

    CAS  Google Scholar 

  11. Dackis CA, Gold MS. Pharmacological approaches to cocaine addiction. J Substance Abuse Treatment. 1985;2:139.

    Article  CAS  Google Scholar 

  12. Dackis CA, Gold MS. Treatment strategies for cocaine detoxification. Lakowski JM, Galloway MP, White FP, eds. In Cocaine: Pharmacology, Physiology, and Clinical Strategies. Boca Raton, Fla: CRC Press; 1992: Chap 19.

    Google Scholar 

  13. Extein IL, Gross DA, Gold MS. Cocaine detoxification using bromocriptine. Am Psychiatric Assoc; 1986. Abstract NR 70.

    Google Scholar 

  14. Giannini AJ, Baumgartel P, Dimarzio LR. Bromocriptine therapy in cocaine withdrawal. J Clin Pharmacol. 1987;27:267.

    PubMed  CAS  Google Scholar 

  15. Malcolm R. Pergolide, bromocriptine trial in cocaine addiction. Am Psychiatric Assoc; 1992. Abstract NR:332.

    Google Scholar 

  16. Tennant FS, Sagherian AA. Double-blind comparison of amantadine hydrochloride and bromocriptine mesylate for ambulatory withdrawal from cocaine dependence. Arch Intern Med. 1987;147:109.

    Article  PubMed  Google Scholar 

  17. Gold MS, Dackis CA. New insights and treatments: opiate withdrawal and cocaine addiction. Clin Ther. 1984;7:6–21.

    PubMed  CAS  Google Scholar 

  18. Dackis CA, Gold MS. New concepts in cocaine addiction: the dopamine depletion hypothesis. Neurosci Biobehav Rev. 1985;9: 469–477.

    Article  PubMed  CAS  Google Scholar 

  19. Spyraki C, Fibinger HC. Behavioral evidence for supersensitivity of postsynaptic dopamine receptors in the mesolimbic system after chronic administration of desipramine. Eur J Pharmacol. 1981;74:195.

    Article  PubMed  CAS  Google Scholar 

  20. Gawin FH. Cocaine addiction: psychology and neurophysiology. Science. 1991;251:1580–1585.

    Article  PubMed  CAS  Google Scholar 

  21. Weiss RD, Mirin SM, and Michael JL. Relapse to cocaine abuse after initiating desipramine treatment. JAMA. 1988;260:2545.

    Article  PubMed  CAS  Google Scholar 

  22. Kosten TR, Morgan CM, Falcione J, Schotenfeld RS. Pharmacotherapy for cocaine abusing methadone maintained patients using amantadine or desipramine. Arch Gen Psychiatry 49:904–908, 1992.

    Article  Google Scholar 

  23. Arndt IO, Dorozynsky L, Woody GE, McLellan AT, O’Brien CP. Desipramine treatment of cocaine dependence in methadone maintenance patients. Arch Gen Psychiatry 49:904–908, 1992.

    Article  Google Scholar 

  24. Pharmacological Effects of Antidepressants, Version II Physicians Postgraduate Press, Inc; 1992.

    Google Scholar 

  25. Meyer RE. New pharmacotherapies for cocaine dependence … revisited. Arch Gen Psychiatry 49:900–904, 1992.

    Article  PubMed  CAS  Google Scholar 

  26. Kosten TR. Behavioral and pharmacologic treatments for cocaine dependence. Treatment challenges in the 1990s. Washington, DC: American Psychiatric Association; May 1992.

    Google Scholar 

  27. Post RM. Time course of clinical effects of carbamazepine: implication for mechanism of action. J Clin Psychiatry. 1988;49(suppl) 4(1):35–46.

    Google Scholar 

  28. Halikas JA, Kuhn KL, Crea FS, et al. Treatment of crack cocaine use with carbamazepine. Am J Drug Alcohol Abuse. 1992;18(1): 45–56.

    Article  PubMed  CAS  Google Scholar 

  29. Gastfriend DR, Mendelson JH, Mello NK, Teoh SK. Preliminary results of an open trial of buprenorphine in the outpatient treatment of combined heroin and cocaine dependence. Committee on Problems of Drug Dependence, 53rd Annual Scientific Meeting; Palm Beach, Fla; June 16–20, 1991.

    Google Scholar 

  30. Grayson NA, Witkin JM, Katz JL, Cowan A, Rice KC. Actions of buprenorphine of cocaine and opiate mediated effects. Committee on Problems of Drug Dependence, 53rd Annual Scientific Meeting; Palm Beach, Fla; June 16-20, 1991.

    Google Scholar 

  31. Kosten TR, Schottenfeld RS, Morgan C, Falcioni J, Ziedonis D. Buprenorphine vs. methadone for opioid and cocaine dependence. Committee on Problems of Drug Dependence, 53rd Annual Scientific Meeting; Palm Beach, Fla; June 16-20, 1991.

    Google Scholar 

  32. Cone E, Holicky B, Pickworth W, Johnson RE. Pharmacologic and behavioral effects of high doses of intravenous buprenorphine. Committee on Problems of Drug Dependence, 53rd Annual Scientific Meeting; Palm Beach, Fla; June 16-20, 1991.

    Google Scholar 

  33. Kosten TR. Behavioral and pharmacologic treatments for cocaine dependence. American Psychiatric Association Symposium: Treatment Challenges in the 1990s. May 1992. Washington, D.C.

    Google Scholar 

  34. Washton AM, Pottash ALC, Gold MS. Naltrexone in addicted business executives and physicians. J Clin Psychiatry. 1984;45(9): 39–41.

    PubMed  CAS  Google Scholar 

  35. Ramsey NF, van Ree JM. Intracerebroventricular naltrexone treatment attenuates acquisition of intravenous cocaine self-administration in rats. Pharm Biochem Behav. 1991;40:807–810.

    Article  CAS  Google Scholar 

  36. Volpicelli JR, Berg BJ, Alterman AI, et al. Naltrexone in the treatment of alcohol dependence. New Research #331, American Psychiatric Association Annual Meeting, Washington DC, May 1992.

    Google Scholar 

  37. Filibeck U, Cabib S, Castellana C, Puglisi-Allegra S. Chronic cocaine enhances defensive behaviors in the laboratory mouse: involvement of the D2 dopamine receptors. Psychopharmacology. 1988;96:437–441.

    Article  PubMed  CAS  Google Scholar 

  38. Goeders NE, Smith JE. Cortical dopaminergic involvement in cocaine reinforcement. Science. 1983; 221(4612):773–775.

    Article  PubMed  CAS  Google Scholar 

  39. Daekis CA, Gold MS, Davies RK, Sweeney DR. Bromocriptine treatment for cocaine abuse: the dopamine depletion hypothesis. Int J Psychiatry Med. 1985;15:125.

    Article  Google Scholar 

  40. Meert TF, Janssen PA. Ritanserin, a new therapeutic approach for drug abuse. Part 2: effects on cocaine. Drug Develop Res. 1992;25:39–53.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Neuroscience and Psychiatry, University of Florida College of Medicine, Gainesville, Florida, USA

    Mark S. Gold M.D.

Authors
  1. Mark S. Gold M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Plenum Publishing Corporation

About this chapter

Cite this chapter

Gold, M.S. (1993). Pharmacological Treatments. In: Cocaine. Drugs of Abuse, vol 3. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-6033-9_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4684-6033-9_7

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4684-6035-3

  • Online ISBN: 978-1-4684-6033-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation